BRD7 Knockout Cell Lysate

Name: BRD7 Knockout Cell Lysate
SKU: DAG-KO342
Rating: 5 (1 reviews)

BRD7 Knockout Cell Lysate from HeLa cell line for anti-BRD7 antibody specificity validation.

COA

SDS

Datasheet

Summary

Product Overview

HeLa cell lines were engineered into double-knockout lines by CRISPR technology. The double knockout genotype was verified by PCR followed by sequencing. The BRD7 knockout cell lysate are the cell homogenate in RIPA buffer made from the KO cell lines. A vial of lysate from the parental cell line was also provided as an internal control.

Nature

Cell Lysate

Alternative Names

BRD7; bromodomain containing 7; bromodomain-containing protein 7; BP75; CELTIX1; protein CELTIX-1; 75 kDa bromodomain protein; NAG4;

Application Notes

Prior to SDS-PAGE fractionation, boil the lysate for 5 minutes.

Dilution

Lysate samples can be diluted with 2x SDS Sample Buffer.
After dilution, the protein sample should be aliquoted and stored at -20°C for long term storage.

Format

Lyophilized

Concentration

The protein concentration was determined with BCA assay.

Buffer

RIPA buffer

Preservative

None

Storage

Store at -20°C. Avoid repeated freeze-thaw cycles.

Citations

Have you cited DAG-KO342 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Up-Regulation of MiR-300 Promotes Proliferation and Invasion of Osteosarcoma by Targeting BRD7

PLOS ONE

Authors: Xue, Zhen; Zhao, Jindong; Niu, Liyuan; An, Gang; Guo, Yashan; Ni, Linying

Abstract

Increasing reports suggest that deregulated microRNAs (miRNAs) might provide novel therapeutic targets for cancers. However, the expression and function of miR-300 in osteosarcoma is still unknown. In our study, we found that the expression of miR-300 was up-regulated in osteosarcoma tissues and cells compared with paired adjacent non-tumor bone tissues and osteoblastic cells using RT-qPCR. The enforced expression of miR-300 could promote cell proliferation, invasion and epithelial-mesenchymal transition (EMT). Moreover, we identified that bromodomain-containing protein 7 (BRD7), a new tumor suppressor gene, was a direct target of miR-300. Ectopic expression of BRD7 could significantly inhibit miR-300-promoted proliferation, invasion and EMT. Therefore, our results identify an important role for miR-300 in osteosarcoma through regulating BRD7 expression.

Preparation of polyclonal antibody highly specific for mouse BRD7 protein and its application

ACTA BIOCHIMICA ET BIOPHYSICA SINICA

Authors: Wang, Heran; Zhao, Ran; Zhou, Ming; Guo, Chi; Liu, Yukun; Jiang, Shihe; Li, Xiayu; Xiong, Wei; Ma, Jian; Peng, Shuping; Li, Xiaoling; Schmitt, David C.; Tan, Ming; Li, Guiyuan

Abstract